Every material Form 8-K Haemonetics filed with the SEC in 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Haemonetics reported second-quarter fiscal 2025 revenue of $345.5 million, up 8.6%, and GAAP diluted EPS of $0.66, up from $0.48 a year earlier. The company reaffirmed its fiscal 2025 adjusted EPS guidance of $4.45 to $4.75, while its organic revenue growth guidance was raised to 1% to 4% from 0% to 3%, and operating cash flow fell to $48.8 million from $99.1 million.
Q2 fiscal 2025 revenue was $345.5 million, up 8.6%; organic revenue rose 3.7%
GAAP net income was $33.8 million, or $0.66 per diluted share, versus $24.9 million, or $0.48, a year earlier
Adjusted EPS was $1.12, up 13.1%; fiscal 2025 adjusted EPS guidance of $4.45 to $4.75 was reaffirmed
Operating cash flow was $48.8 million versus $99.1 million, and free cash flow was $37.0 million versus $75.0 million
Haemonetics disclosed that Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave the company on November 1, 2024. The filing describes her as a named executive officer and gives no successor or reason for the departure.
Anila Lingamneni, Executive Vice President and Chief Technology Officer, will leave on November 1, 2024
The departure is listed under Item 5.02 for a named executive officer
The filing does not name a successor or give a reason for the departure
The 8-K was signed by CEO Christopher A. Simon on September 16, 2024
Haemonetics reported first quarter fiscal 2025 results for the period ended June 29, 2024, with revenue up 8.0% to $336.2 million, while GAAP earnings per diluted share fell to $0.74 from $0.80 and adjusted earnings per diluted share fell 2.9% to $1.02. The company reaffirmed its fiscal 2025 revenue, adjusted operating margin, adjusted earnings per share and free cash flow guidance, so shareholders see stronger sales but lower profit in the quarter with no change to the full-year outlook.
Revenue was $336.2 million, up 8.0% from the prior year; organic revenue grew 2.8%, with Hospital up 30.7% and Plasma down 2.7%.
GAAP operating income was $39.8 million, an 11.8% margin, versus $53.7 million and a 17.2% margin a year earlier.
Operating cash outflow was $27.4 million and free cash outflow was $16.9 million, compared with operating cash inflow of $19.1 million a year earlier.
Fiscal 2025 adjusted earnings per diluted share guidance of $4.45 to $4.75 was reaffirmed.
Haemonetics completed the issuance of $700 million of 2.50% convertible senior notes due June 1, 2029 on May 28, 2024, including $100 million from the full exercise of the initial purchasers' option. The company used the proceeds to pay $88.2 million for capped call transactions, repurchase $200.0 million of its 0.00% convertible notes due 2026 for $185.5 million in cash, and repay the $230.0 million revolving credit balance in full.
$700 million of 2.50% convertible senior notes due June 1, 2029, issued May 28, 2024
Initial conversion price of about $117.12 per share; capped call cap price initially $180.18
Proceeds: $88.2 million for capped calls, $185.5 million to repurchase $200.0 million of 2026 notes, $230.0 million revolver repaid
Notes are senior unsecured obligations; interest payable semi-annually beginning December 1, 2024
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Haemonetics filing is on SEC EDGAR ↗. 8-K briefs of other companies →